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Abstract
We are creating families of designer G-protein-coupled receptors (GPCRs) to allow for precise
spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called receptors
activated solely by synthetic ligands (RASSLs), are unresponsive to endogenous ligands but can be
activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules.
Currently, RASSLs exist for the three major GPCR signaling pathways (Gs, Gi, Gq). These new
advances are reviewed here to help facilitate the use of these powerful and diverse tools.
G-protein-coupled receptors (GPCRs) are an ideal vehicle for engineering synthetic signaling
systems. These receptors function as signaling switches throughout the body and regulate
virtually every physiological response1-3. GPCRs are also the largest gene family targeted for
drug discovery4. GPCRs stimulate a variety of G protein pathways; for example, Gs stimulates
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cAMP production, Gi inhibits cAMP production, and Gq stimulates phospholipase C and
releases intracellular calcium stores. Since GPCRs have a relatively simple modular design
and are encoded by small genes (usually <1.5 kb), engineered GPCRs can be easily transferred
without loss of their functionality into different tissues and species. Finally, designer GPCRs
could be useful for regulating physiologic processes and engineering tissues with stem cells
and other technologies.
Attempts to engineer GPCRs that are activated solely by pharmacologically inert drug-like
molecules have met with varying degrees of success (Table 1). Engineered receptors and
engineered receptor/ligand pairs have been created by several approaches and bear different
names—receptors activated solely by synthetic ligands (RASSLs)5, therapeutic receptor-
effector complexes (TRECs)6, neoceptors7, and designer receptors exclusively activated by
designer drugs (DREADDs)8. Here we will refer to them as RASSLs, and we propose a
consensus nomenclature (Table 1) for those in widespread use or in development. This
nomenclature links the name of the parent receptor to the major G-protein signaling pathway
activated by the receptor.
Engineering RASSLs by directed mutagenesis
In the first attempt to make a designer GPCR, Strader and colleagues developed a series of
compounds to selectively activate a mutant version of the ••-adrenergic receptor (••-AR) that
was unresponsive to its natural hormone9. This group focused on D1133.32, which is conserved
among all biogenic amine GPCRs and is critical for binding terminal amine groups (Fig. 1).
Mutating D1133.32 to Ser greatly reduced activation of the •2-AR by biogenic amines.
Remarkably, this mutation enabled the newly synthesized butanone derivative, 1-(3',4'-
dihydroxyphenyl)-3-methyl-1-butanone (L-185,870), to activate the mutant receptor but not
the wildtype (WT) receptor, albeit with relatively low potency (EC50=118 •M)9. Although this
original report was inspiring, the synthetic agonist had low affinities and unknown
pharmacokinetics that rendered it impractical for in vivo use.
The first engineered receptor or RASSL activated by an agonist with nanomolar affinity
suitable for in vivo use was reported by Coward et al.5, who took advantage of potent synthetic
drugs originally developed as potential analgesics, such as •-opioid receptor (KOR) agonists
(e.g., spiradoline). The first RASSL was created by introducing mutations in the KOR that
abrogated signaling via the natural peptide ligands, yet preserved stimulation by
spiradoline5. This engineered human RASSL (hRO-i; h=human, R=RASSL, O=Opioid,
i=Gi; referred to as Ro15, a Gi-coupled receptor, has been expressed in at least six tissues (Fig.
2) in transgenic animals. Diverse phenotypes were induced, including ligand-dependent heart-
rate modulation10, bitter and sweet taste sensations11,12, and ligand-independent
cardiomyopathy13, hydrocephalus14, and osteopenia15. These exciting results fueled efforts
to develop RASSLs with improved ligand pharmacology and a greater range of signaling
responses.
Once scientists understood that RASSLs could be designed to work with existing drugs, new
RASSLs soon emerged from studies of a wide variety of receptors, including the 5-HT4
serotonin16, •2-adrenergic6, H1-histamine17, A3 adenosine7, 5-HT2A-serotonin18, and MC4-
melanocortin19 receptors. In most, key residues essential for binding the native ligand were
targeted by site-directed mutagenesis. For example, introduction of the D1003.32A mutation
(analogous to the D1133.32A mutation in the •2-AR9) into the Gs-coupled human 5-HT4
serotonin receptor abolished the ability of 5-HT to activate the receptor but did not affect the
activity of many synthetic agonists, including carbazimidamides, benzamides,
benzimidazolones, and aryl ketones; this RASSL, previously known as Rs1, will be referred
to as hRS-s16. Many of these synthetic agonists have drug-like properties, nanomolar affinities,
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and readily penetrate the central nervous system and can therefore be used effectively in
vivo16,20. In addition, hRS-s is activated by antagonists of the 5-HT4 receptor, which have
fewer in vivo side effects than 5-HT4 receptor agonists. Intriguingly, when expressed in
osteoblasts of young mice, hRS-s dramatically alters bone growth in vivo21, presumably due
to constitutive activation of the Gs pathway. These experiments provide valuable insights into
the specific cellular and temporal factors that allow Gs signaling to induce bone growth.
This same mutagenesis approach of replacing conserved residues of the binding pocket with
alanines has been applied to other biogenic amine receptors. Thus, mutation of a conserved
serine residue in the fifth transmembrane region (S2045.46A) led to a sizeable loss of affinity
and efficacy of (-)-adrenaline at •2A-adrenoceptors (Gi/o-coupled receptors), while the mutated
receptor could still be activated by synthetic agonists (UK14304, clonidine) or even by
antagonists of the WT receptor (atipamezole, SKF86466)22. Similarly, a Gq/11-coupled
RASSL was obtained by introducing the F4356.55A mutation into the histamine H1
receptor17. This RASSL could be activated by high concentrations of endogenous histamine
and had improved affinity and potency for 2-phenylhistamines, a class of synthetic H1R
agonists (2-[3-chlorophenyl]histamine). Interestingly, alternative substitutions at this position
(F4356.55) resulted in RASSLs with different levels of constitutive activity; F4356.55A (hRH-
s) had the lowest level of constitutive signaling.
Creating RASSLs by directed molecular evolution
Despite these noteworthy advances, first-generation RASSLs were not ideal for
experimentation. The ligands of first-generation RASSLs activated endogenous receptors (e.g.,
•-opioid, H1-histamine, 5-HT4-serotonin, MC4-melanocortin), and had low affinities for the
mutated receptor (A3-adenosine neoceptor; ••-AR TREC; 5-HT2A serotonin RASSL).
Moreover, profound phenotypes induced by constitutive activity were observed upon RASSL
overexpression in vivo (RO-i and RS-s). Finally, development of new RASSLs by repeated
cycles of directed mutagenesis was labor intensive and did not consistently yield receptors with
ideal agonist affinities or controlled levels of constitutive signaling. To overcome these
inherent difficulties, we developed a generic approach to create a new class of RASSLs that
have low constitutive activity and respond specifically to drug-like, pharmacologically inert
small molecules8.
We used a well-established yeast mutagenesis system to produce hundreds of thousands of
mutant hM3 muscarinic receptors and screened them for signaling characteristics of an “ideal”
RASSL8. After multiple rounds of mutagenesis and iterative screening, we isolated mutants
that had lost the ability to respond to the natural ligand (acetylcholine) but gained the ability
to respond with nanomolar potency to clozapine-N-oxide (CNO), a pharmacologically inert,
bioavailable23 synthetic compound (Fig. 3). This new class of RASSLs was designated
DREADDs (ref. 6). We will refer to this first DREADD as “hRMD-q” (RASSL M3 DREADD,
Gq-coupled; referred to as hM3-D in ref. 6). The RMD-q receptor is insensitive to acetylcholine
but activates the Gq pathway to induce calcium mobilization upon binding of CNO. Analogous
mutations in the closely related M4 muscarinic receptor, which is Gi-coupled and inhibits
cAMP accumulation, led to another RASSL/DREADD that we call hRMD-i (referred to as
hM4D8). Intriguingly, when activated by CNO, hRMD-i silenced hippocampal neurons via
G••-mediated activation of G-protein inwardly rectifying K+ (GIRK) channels8. It is likely
that hRMD-i will be widely used to induce neuronal silencing in vivo via indirect activation of
GIRKs. More recently, (Guettier, J.M., et al abstract, International Group on Insulin Secretion,
St. Jean Cap-Ferrat, France; 2007), made chimeras of the rat equivalent of the hRMD-q that
incorporates the second and third intracellular loops of the Gs-coupled •1 adrenergic receptor
to create a Gs-coupled RASSL (rRMD-s, see table 1). Thus, CNO can be used to activate the
Gs, Gi, or Gq signaling pathways, depending on which of the new RASSLs is utilized.
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With the current DREADD-type RASSLs, only two point mutations were required to create
hRMD-I and hRMD-q. By contrast, the rRMD-s required two point mutations and swapping
of two intracellular loops. Creating other DREADD-type RASSLs by directed molecular
evolution will likely require at least multiple point mutations based on our own unpublished
experience (Pei et al, in preparation). Thus far, all of the point mutations have been found in
or near predicted binding sites for orthosteric ligands.
The general method we devised evolves GPCR ligand specificity toward pharmacologically
`inert” ligands (e.g., drug-like compounds without known molecular targets). This technique
is likely to be widely used to create designer GPCRs, owing to the availability of strains of
yeast (Saccharomyces cerevisiae) engineered to express and respond to human GPCRs24,25.
When these GPCR-expressing yeast are activated by an agonist, the signal induces the
expression of a variety of selectable markers under control of a Fus-1 promoter. This system
allows for the facile screening and optimization of millions of mutant GPCRs in a relatively
short time26. Dozens of human GPCRs have been expressed in yeast27, thereby opening up
the potential to create families of designer GPCRs activated by specific small molecules.
RASSLs as molecular switches for tissue engineering
RASSLs may be valuable in controlling growth and ensuring appropriate control of function
for experimental or therapeutic tissue engineering. GPCR signaling is essential for the growth
and differentiation of many tissues2. For example, the 5-HT2B serotonin receptor is required
for cardiac development and cell-cycle progression28-30. Ectopic signaling via GPCRs can
promote abnormal growth3, leading to human disease. For instance, drug-induced valvular
heart disease may be caused by excessive stimulation of cardiac 5-HT2B receptors31. One can
envision the use of RASSLs to activate discrete signaling pathways to promote the proper
growth and differentiation of engineered tissues.
Another potential use of RASSLs is to gain precise control of signaling in neurons and other
tissues. Currently, this control in defined neuronal populations can be facilitated by expressing
RASSLs in a neuron-specific manner. We reported that CNO-mediated activation of the Gi-
coupled hRMD-i induces neuronal silencing when expressed in hippocampal neurons8. When
expressed in hippocampal neurons, hRMD-q induces neuronal excitation and intracellular
Ca++ release in CNO-dependent fashion (Rogan and Roth, manuscript in preparation). Using
these two engineered muscarinic receptors, one could gain precise bi-directional control of
neuronal firing in vitro and in vivo. These modified receptors could also be used in other
excitable tissues, such as cardiac pacemaker cells, where Gs stimulation speeds diastolic
depolarization and accelerates heart rate, and Gi stimulation slows heart rate. Expression of
different Gs (e.g., hRS-s or rRMD-s) and Gi (e.g., RO-i or hRMD-i) RASSLs in pacemaker
cells could allow for the precise regulation of heart rate without affecting cardiac muscle
function.
The importance of constitutive signaling by RASSLs
In studies of first-generation RASSLs expressed in vivo, constitutive signaling (constitutive
activity) has often produced the most profound effects. Overexpression of a Gi-coupled RASSL
(hRO-i) in cardiomyocytes led to cardiomyopathy13, while overexpression in osteoblasts led
to osteoporosis15. Recently a Gs RASSL (hRS-s) expressed in osteoblasts induced marked
bone growth15. Constitutive activity is a common property of native GPCRs32,33 and is
essential for the normal function of certain GPCRs34. Therefore, RASSLs with different levels
of constitutive activity (high and low) will be needed to recapitulate normal GPCR functions.
Because of the potential ligand-independent effects, RASSL expression ideally should be
controlled through conditional expression systems (e.g., Tet or Cre). With these systems, a
single RASSL transgenic line can be used to drive expression in diverse tissues with tighter
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temporal control. The second-generation RASSLs (hRMD-q, hRMD-i, rRMD-s) were created
to lack constitutive activity8, and thus far, their overexpression in mice has not elicited baseline
phenotypes (Rogan, Roth, Guettier and Wess, unpublished observations). These second-
generation RASSLs will be most useful for studies in which ligand-dependent effects (rather
than baseline phenotypes) are sought.
Future directions
The RASSL field has undergone dramatic growth in the past decade, but many more challenges
lie ahead. For instance, the ideal family of RASSLs would respond to a clinically approved,
biologically inert drug (e.g., antibiotic or antiviral) that has no intrinsic effect on human cells,
allowing tissue engineering without the drug safety studies needed for relatively new
compounds such as CNO. The optimal series of RASSLs would also selectively couple to each
of the GPCR pathways, including noncanonical pathways, such as those involving arrestins,
GRKs, and intracellular kinases29. Furthermore, each RASSL would have different
constitutive responses, desensitization properties, and subcellular targeting that could be fine-
tuned with simple mutations. For many of these goals, we will need spatiotemporal control of
RASSL expression to allow for direct comparisons of RASSL actions that could be applicable
to virtually any tissue. Several groups are now testing a variety of approaches (BAC
transgenics, knock-ins, and inducible systems) to meet these new challenges and provide new
tools to RASSL researchers. With these highly refined tools, biologists will have a better
understanding of how to use RASSLs and GPCR signaling pathways for tissue engineering.
The cross-disciplinary nature of RASSL-related research fosters a highly collaborative
community that makes protocols, reagents, and transgenic animals publicly available whenever
possible. Even though individual members of the RASSL community initially created tools
specifically for their own research, the potential uses of these tools go well beyond any
individual project. Indeed, precisely because GPCR signaling is important to such a wide swath
of biology, it is impossible for us to accurately predict how and where RASSLs will be
ultimately used.
We anticipate that our RASSL delivery systems will be deployed for a wide range of tissue
engineering applications in neurological disease, pain perception, immunology, bone
metabolism, and diabetes. In each case, our efforts will provide enabling technologies to rapidly
advance those fields. For instance, in many neurological diseases (e.g., Parkinson's disease),
RASSLs may be useful for correcting the imbalance of neural pathways, in a manner that could
complement the surgical/electrical approaches in current clinical practice. Similarly, many
groups envision using tissue-engineering approaches to study pain perception pathways.
RASSLs, which selectively modulate neuronal firing, should be ideal for this application.
Although GPCRs are clearly important in bone metabolism, many key receptors signal via
multiple pathways and exhibit constitutive signaling. RASSLs allow researchers to stimulate
discrete signaling pathways in bone metabolism. Finally, in diabetes, GPCRs play a role in the
growth, development, and function of insulin-secreting pancreatic •-cells35. Dissecting the
precise roles of different G-protein signaling pathways in •-cell function should be of
considerable therapeutic interest.
Perhaps most importantly, the use of RASSL technology may shed light on relatively unknown
aspects of GPCR signaling. For instance, many researchers are investigating nonclassical
signaling responses of GPCRs, such as signaling by G12/13, arrestins, receptor kinases,
regulators of G protein signaling, Wnt receptor signals, and scaffolding proteins29. It should
be of interest to create two RASSLs that only differ in their ability to activate the arrestin
pathways. Expression of these two RASSLs in the same spatial and temporal pattern would
then allow determination of the true physiological roles of arrestin signaling.
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Some of these non-G-protein signaling pathways could prove essential for robust tissue
engineering and for uncovering the pathways responsible for stem cell differentiation. One can
envision scenarios in which RASSLs are selectively expressed in different stem cell lineages
and then activated (with an exogenous ligand or by overexpression) to determine which
pathways are responsible for lineage choices and tissue differentiation.
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Creating RASSLs by targeted mutagenesis. A conserved residue(s) in the canonical binding
pocket of biogenic amine receptors (e.g., adrenergic, serotonin, histamine) is mutated to
eliminate the binding and activation of the receptor for the native ligand. A model using the
coordinates of the ••-adrenergic receptor structure30 is used to illustrate this. In all biogenic
amine GPCRs, the binding pocket is composed of a conserved aspartic acid (D1133.32 in the
•2-AR model; SIDE VIEW) and conserved aromatic and polar residues (TOP VIEW). Mutation
of the highly conserved Asp to Ser (D113S) renders the •2-AR insensitive to •-AR exogenous
and endogenous agonists, such as isoproterenol, epinephrine, and norepinephrine. However,
the D113S mutant receptor could be activated by the synthetic ligand L-185, 870. Such a
targeted mutagenesis approach was used to create both peptidergic RASSLs (e.g., •-opioid,
MC4-melanocortin) and nonpeptidergic RASSLs (H1-histamine, 5-HT2A serotonin, 5-HT4
serotonin, •2-adrenergic) (see text for details).
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Myriad ligand-dependent and -independent phenotypes are induced by tissue-specific
expression of a single RASSL. Ligand-induced phenotypes are noted in red; constitutive
signaling-induced phenotypes are in blue. Asterisks indicate tissues in which RO1 expression
results in embryonic or perinatal lethality. Conditional expression allows RASSL researchers
to avoid embryonic lethality and analyze adult phenotypes.
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Directed molecular evolution to create novel RASSLs. Shown is a generic scheme for obtaining
RASSLs via directed molecular evolution. In brief, a large library of randomly mutated GPCRs
is obtained by error-prone PCR and used to efficiently transform the appropriate yeast strain.
Yeast with functional GPCRs is grown in histidine-deficient medium in the presence of the
inert ligand (in this case clozapine-N-oxide, CNO), and surviving colonies are expanded and
characterized pharmacologically. GPCRs with the appropriate pharmacological profiles are
subjected to iterative rounds of additional mutagenesis and selection until the ideal RASSL is
obtained. Candidate RASSLs are subjected to growth assays in the presence and absence of
candidate ligands to screen out those with elevated levels of constitutive activity. Typically
several candidate inert ligands are used in the initial screens to determine which are most
suitable for directed molecular evolution and then one or more chosen for further testing. The
final choice of the candidate ligand is based on its potency and drug-like properties.
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Signaling notes Agonist and antagonists
(relative affinities in nM)
In vivo phenotypes
hRO-i Ro15,10: human kappa












sweet taste, bitter taste,
bone. See Figure 1.
Spiradoline (low nM)
Salvinorin A (low nM)
Antagonist:
hRO3-i (RO3 or Rog)36:
same as Ro1, but with





hRS-s Rs1 16,20,21: human
serotonin 4 receptor with






Agonist Massive increase in
bone formation
RS67333, RS39604, Cisapride,
ML10375, GR113808 (all nM)

















Gq signaling Agonist None known
CNO (low nM)
Antagonist






RASSL is also Gi coupled
Gi signaling Agonist Inhibits electrical
signaling in brain slices
CNO (low nM)
Antagonist
Atropine (reduced affinity vs.
WT; high nM)
rRMD-s DREADD RASSL2: rat




Gs signaling Agonist None known
CNO (low nM)
Antagonist
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Name Alternative names:
major versions
Signaling notes Agonist and antagonists
(relative affinities in nM)
In vivo phenotypes
Atropine (reduced affinity vs.
WT; high nM)
This table only includes RASSLs that are actively used in transgenic animals and have a commercially available ligand with low side effects. A uniform
RASSL naming system is used. For instance hRMD-q stands for: h=human, R=RASSL, M=Muscarinic, D=DREADD, q=signaling via Gq. The shortest
possible name is used. For the parent RASSL we do not add a number but numbers can be added, to indicate versions. For instance hRO3-i, is a GFP
tagged version of hRO-i.
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